Evidence map›Paper›PMID 39803449›Full record

ArticlebioRxiv : the preprint server for biology2025

Neuronal LAG3 facilitates pathogenic α-synuclein neuron-to-neuron propagation.

Xiuli Yang, Deok Jeong, Graziella Madeo, Ramhari Kumbhar, Ning Wang, Lili Niu, Junkai Hu, Shuya Li, Kundlik Gadhave, Rong Chen and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiuli YangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Deok JeongNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Graziella MadeoCellular Neurobiology Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224, USA.
Ramhari KumbharNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ning WangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Lili NiuNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Junkai HuNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Shuya LiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kundlik GadhaveNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Rong ChenNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Fatih AkkentliNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Creg J WorkmanDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Mingyao YingDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Antonello BonciCellular Neurobiology Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224, USA.
Valina L DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6459-0893
Xiaobo MaoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-6587-556X

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Arlene H. Sharpe · 2015 to 2026
$30.8M
Murine Mutagenesis CoreP30NS050274 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOLODKIN, ALEX L · 2005 to 2020
$10.9M
Structure, Function and Mechanistic Analysis of LAG3R01AI144422 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roy A Mariuzza, Dario AA Vignali · 2019 to 2026
$5.9M
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's DiseaseR01AG073291 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$3.2M
MIF Nuclease actions in Synuclein DementiasR01AG085688 · NIA · JOHNS HOPKINS UNIVERSITY · PI VALINA L. DAWSON, Ted M. Dawson · 2024 to 2026
$2.4M
Determine the role of atmospheric particulate matter pollutants in contributing to Lewy Body DementiaRF1AG079487 · NIA · JOHNS HOPKINS UNIVERSITY · PI LIU, PENGFEI, MAO, XIAOBO · 2023 to 2023
$2.3M
Novel fibril-selective nanobody-based agents targeting intracellular and extracellular α-synuclein aggregates and prion-like propagation induced dementiaRF1NS137428 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAO, XIAOBO, WANG, WENJING · 2024 to 2024
$2.3M
Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein SpreadingR01AG071820 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$2.3M
α-Synuclein strain properties are associated with diagnosis of and progression to Parkinson's disease with dementiaRF1NS125592 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO, ROSENTHAL, LIANA ISA SHAPIRO · 2022 to 2022
$2.1M
Understanding the Mechanism of Pathological alpha-Synuclein TransmissionR01NS107318 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2019 to 2023
$2.0M
The cross-talk between a-Synucleinopathies and T cell immunity in ADRDR01AG089605 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO, PENG, WEIYI · 2024 to 2025
$1.6M
NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI144422NIA NIH HHS K01 AG056841NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG071820NIA NIH HHS R01 AG073291NIA NIH HHS R01 AG085688NIA NIH HHS R01 AG089605NIA NIH HHS RF1 AG079487NINDS NIH HHS P30 NS050274NINDS NIH HHS R01 NS107318NINDS NIH HHS R21 NS125559NINDS NIH HHS RF1 NS125592NINDS NIH HHS RF1 NS137428
6 · The paper itself

Abstract

Lymphocyte activation gene 3 (LAG3) is a key receptor involved in the propagation of pathological proteins in Parkinson's disease (PD). This study investigates the role of neuronal LAG3 in mediating the binding, uptake, and propagation of α-synuclein (αSyn) preformed fibrils (PFFs). Using neuronal LAG3 conditional knockout mice and human induced pluripotent stem cells-derived dopaminergic (DA) neurons, we demonstrate that LAG3 expression is critical for pathogenic αSyn propagation. Our results show that the absence of neuronal LAG3 significantly reduces αSyn pathology, alleviates motor dysfunction, and inhibits neurodegeneration

Indexed as

electrophysiologyLAG3neuronPFFsα-synuclein

Identifiers

PMID39803449
PMCPMC11722393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.